Skip to main content
Sign In

Brandon McMahon, M.D.

Brandon McMahon, M.D.
University of Colorado School of Medicine

Associate Professor of Medicine





Dr. McMahon is an adult hematologist, whose expertise is in thrombotic disorders and myeloproliferative neoplasms (MPN). His research interests are in mechanisms of aberrant coagulation in specific disease states, including cancers/MPN. He is also interested in clinical trials & drug development in these areas. Medical education is also one of his focuses and priorities.    



​Dr. McMahon completed his undergraduate training at Boston College, where he received a Bachelor’s degree in Chemistry with honors.  He graduated AOA with his M.D. from SUNY-Upstate Medical University at Syracuse, and then moved to the University of Rochester where he completed his internal medicine residency, followed by a chief residency.  He remained that the University of Rochester for his hematology fellowship, which was completed in 2007, and during which he completed the American Society of Hematology Clinical Research Training Institute.    

He joined the faculty at Northwestern University in Chicago as an Assistant Professor and later Associate Professor of Medicine, where he was heavily involved in clinical operations in hematology, clinical research in thrombotic disorders and MPN, and education, receiving multiple teaching awards and serving as the associate and later director of the Hematology/Oncology fellowship program.  He joined the faculty at the University of Colorado in 2016, and will be focusing on thrombosis & MPN in the clinical arena, while remaining active in fellow & resident education.  


Dr. McMahon’s research involves evaluating mechanisms of thrombotic and bleeding complications in various cancers (particularly MPN), critical evaluation of common medical practices in hematology that lack significant evidence basis, and clinical trials evaluating new therapeutic developments in MPN.  He has written many peer-reviewed papers on these topics, several book chapters, and edited a recently published textbook on myeloproliferative neoplasms.   


  • Boston College, BS, 1997

  • State University of New York, Upstate Medical University, Syracuse, MD, 2001

  • University of Rochester Medical Center, Internship and Residency in Internal Medicine, 2004

  • University of Rochester Medical Center, Chief Medical Residency 2005

  • University of Rochester Medical Center, Hematology Fellowship, 2007

​Dr. McMahon’s research focus has been on mechanisms of abnormal bleeding and clotting in specific disease states, particularly cancers/myeloproliferative neoplasms.  This includes evaluating clinical risk factors for developing thrombotic or bleeding complications in specific disease states.  He is also interested in clinical trials investigating novel therapeutic options in MPN.  

Dr. McMahon’s past work has also evaluated use of diagnostic testing or therapeutic interventions in hematology that lack clinical validation, yet are commonly used in everyday practice.  ​

  1. Waisbren, J; Dinnner, S; Altman, J; Frankfurt, O; Helenowski, I; Gao, J; McMahon, B; and Stein, BL.  Disease characteristics and prognosis of myelodysplastic syndrome presenting with isolated thrombocytopenia. Int J Hematol2016; epub ahead of print.

  2. McMahon, B and Kamath, S.  Pancytopenia in a patient with hypothyroidism.  JAMA 2016; 315(15): 1648.

  3. Buck, R; Wachsberg, KN; Weaver, AC; Hansen, LO; McMahon, B; Dombrowski, L; and O’Leary, K. Survey of provider transfusion practices for oncology patients in an academic medical center.  South Med J 2016; 109(4): 267-71.  

  4. Kamath, S and McMahon, B. Update in anticoagulation: what IR needs to know. Semin Intervent Radiol 2016; 33(2): 122-31. 

  5. Kaplan JB; Stein BL; McMahon B; Giles FJ; and Platanias L. Evolving therapeutic strategies for the classic Philadelphia negative myeloproliferative neoplasms. EBioMedicine 2016; 2016; 3: 17-25.  

  6. Yentz, S; Onwuemene, O; Stein, BL; Cull, E; McMahon, B.  Clinical use of anti-Xa monitoring in malignancy associated thrombosis. Thrombosis 2015; 2015: 126975.

  7. McMahon, B and Kwaan, HC.  Components of the plasminogen-plasmin system as biologic markers for cancer. Adv Exp Med Biol 2015; 867: 145-56.

  8. Kander, EM; Raza, S; Zhou, Z; Gao, J; Zakarija, A; McMahon, B; and Stein, BL.  Bleeding complications in BCR-ABL negative myeloproliferative neoplasms: prevalence, type, and risk factors in a single-center cohort.  In J Hematol 2015;102(5): 587-93.

  9. Saleiro, D; Mehrotra, S; Kroczynska, B; Beauchamp, E; Lisowski, P; Majchrzak-Kita, B; Bhagat, T; Stein, BL; McMahon, B; Altman, JK; Kosciuczuk, E; Baker, D; Jie, C; Jafari, N; Thompson, C; Levine, R; Fish, E; Verma, A; and Platanias, LC.  Central role of ULK1 in type I interferon signaling.  Cell Reports 2015; 11: 605-617.

  10. McMahon, B and Kwaan, HC.  The new or non-vitamin K antagonist oral anticoagulants (NOACs): what we have learned since their debut.  Semin Thromb Hemostasis 2015; 41: 188-194.

  11. Prince, BT; McMahon, BJ; Jain, M; and Peters, AT.  Meropenem tolerance in a patient with probably fulminant pipercillin-induced immune hemolytic anemia. J Allergy and Clinical Immunology: In practice 2015; 3(3): 452-53.   

  12. Martin, K; Kia, L; Parikh, ND; Kulik, L; and McMahon, B.  Heparin-induced thrombocytopenia testing is over-utilized in cirrhosis & correlates with poor clinical outcome.  Ann Hepatol 2014; 13(5): 548-54.

  13. Kwaan, HC; McMahon, BJ; Hylek, EM.  Age-related changes in thrombosis and hemostasis.  Semin Thromb Hemost 2014; 40(6): 619-20.

  14. McMahon, B and Kwaan, HC. Thrombocytopenia in older adults.  Semin Thromb Hemostasis 2014; 40(6): 682-687. 

  15. Kaur S, Kroczynska B, Sharma B, Sassano A, Arslan AD, Majchrzak-Kita B, Stein BL, McMahon B, Altman JK, Su B, Calogero RA, Fish EN, Platanias LC.  Critical Roles for Rictor/Sin1 complexes in IFN-dependent gene transcription and generation of antiproliferative properties.  J Biol Chem 2014; 289: 6581.

  16. McMahon, B.  Meeting report of the 55th American Society of Hematology Meeting: Benign Hematology. New England Journal of Medicine Journal Watch Feb 2014; 9 (2): 12.

  17. McMahon, B. and Martin, K. Successful coronary artery bypass grafting in a patient with severe factor VII deficiency, with minimal use of recombinant factor VIIa.  Haemophilia 2014; 20(1): e94-7.  

  18. Crawford J, Armitage J, Balducci L, Becker PS, Blayney DW, Cataland SR, Heaney ML, Hudock S, Kloth DD, Kuter DJ, Lyman GH, McMahon B, Rugo HS, Saad AA, Schwartzberg LS, Shayani S, Steensma DP, Talbott M, Vadhan-Raj S, Westervelt P, Westmoreland M, Dwyer M, Ho M.  Myeloid growth factors. J Natl Compr Canc Netw 2013; 11(10): 1266-90. 

  19. Mehrotra S, Sharma B, Joshi S, Kroczynska B, Majchrzak B, Stein BL, McMahon B, Altman JK, Licht JD, Baker DP, Eklund EA, Wickrema A, Verma A, Fish EN, Platanias LC.  Essential role for the Mnk-pathway in the inhibitory effects of Type I interferons on myeloproliferative neoplasm (MPN) precursors. J Biol Chem 2013; 288 (33): 23814-22.

  20. Kwaan, HC; Mazar, AP; McMahon, B.  The apparent uPA/PAI-1 paradox in cancer: more than meets the eye. Semin Thromb Hemost 2013; 39 (4): 382-391.

  21. McMahon, B.  Heterogeneity in the myelodysplastic syndromes: moving toward a better understanding. Leuk Lymphoma 2013; 54(5): 907-8. 

  22. Stein, BL; Saraf S.; Sobol, U.; Halpern, A.; Shammo, J.; Rondelli, D.; Michaelis, L.; Odenike, O.; Rademaker, A.; Zakarija, A.; McMahon, B.; Spivak, JL; and Moliterno, AR. Age-related differences in disease characteristics and clinical outcomes in polycythemia vera. Leuk Lymphoma 2013; 54(9): 1989-95. 

  23. McMahon, B. and Stein, BL. Thrombotic and bleeding complications in the classical myeloproliferative neoplasms.  Semin Thromb Hemost 2013; 39(1): 101-111. 

  24. McMahon, B. and Kwaan, HC.  Thrombotic and bleeding complications associated with chemotherapy. Semin Thromb Hemost 2012; 38 (8): 808-817. 

  25. Sharma B.; Joshi, S.; Sassano, A.; Majchrzak, B.; Kaur, S.; Aggarwal, P.; Nabet, B.; Bulic, M.; Stein, B.; McMahon, B.; Baker, D.; Fukunaga, R.; Altman, J.; Licht, J.; Fish, E.; and Platanias, L.  Sprouty proteins are negative regulators of interferon (IFN) signaling and IFN-inducible biological responses.  Journal of Biological Chemistry 2012; 287(50): 42352-60.

  26. Crawford J, Allen J, Armitage J, Blayney DW, Cataland SR, Heaney ML, Htoy S, Hudock S, Kloth DD, Kuter DJ, Lyman GH, McMahon B, Steensma DP, Vadhan-Raj S, Westervelt P, Westmoreland M; National Comprehensive Cancer Network.  Myeloid Growth Factors.  J Natl Compr Canc Netw 2011; 9(8): 914-32.

  27. Ruch, J.; McMahon, B.; Ramsey, G. and Kwaan, H. Catastrophic multiple organ ischemia due to an anti-Pr cold agglutinin developing in a patient with mixed cryoglobulinemia after treatment with Rituximab. Am J Hematol 2009: 84(2): 120-22.

  28. McMahon, B. Malignancy associated thrombosis. Oncology Issues 2009; 24: 20-23.

  29. Stein, E.; McMahon, B.; Kwaan, H.; Altman, J.; Frankfurt, O.; and Tallman, M. The coagulopathy of acute promyelocytic leukaemia revisited. Best Pract Res Clin Haematol 2009; 22: 153-63.

  30. McMahon, B. and Kwaan, H. The plasminogen activator system and cancer. Pathophysiol Haemost Thromb 2008; 36: 184-94.

  31. Green, D.; McMahon, B.; Foiles, N. and Tian, L.  Measurement of hemostatic factors in EDTA plasma. J of Clinical Pathology 2008: 130 (5): 811-815. 

  32. Scott, LT; Boorum, M; McMahon, BJ; Hagen, S; Mack, J; Blank, J; Wegner, H; and deMeijere, A. A rational chemical synthesis of C60. Science 2002; 295 (5559): 1500-03.

  33. Antzelevitch, C; Shimizu, W; and McMahon, B. Sodium pentobarbital reduces transmural dispersion of repolarization and prevents Torsade de Pointes in models of acquired and congenital long QT syndrome.  J Cardiovasc Electrophysiol 1999; 10: 154-64.

Books and Book Chapters​

  1. Kwaan, HC and McMahon, B. Abnormalities in the fibrinolysis pathway and clinical implications. In: Abutalib SA et al ed. Nonmalignant Hematology. Springer International Publishing, Switzerland; 2016.

  2. Stein, BL and McMahon, B (editors). Contemporary Management of Myeloproliferative Neoplasms.  New Delhi: Jaypee Brothers Medical Publishing, 2015. Print.

  3. McMahon, B. Thrombotic and bleeding complications in myleoproliferative neoplasms.  In: Stein, BL & McMahon, B eds. Contemporary Management of Myeloproliferative Neoplasms.  New Delhi: Jaypee Brothers Medical Publishing; 2015: 52. 

  4. McMahon, B. and Kwaan, H.  Components of the plasminogen-plasmin system as biologic markers for cancer.  In: Bigelow, D ed.  Advances in Experimental Medicine and Biology. Springer; 2015: 145.

  5. McMahon, B. Utility of D-Dimer in predicting recurrence in idiopathic venous thromboembolic disease. In: Eskandari, MK; Morasch, MD; Pearce, WH; and Yao, J eds. New Findings in Vascular Surgery. Shelton, CT: People’s Medical Publishing House; 2011: 141.

  6. McMahon, B. and Kwaan, H. The role of plasminogen-plasmin system in cancer. In: Green, D & Kwaan, HC eds. Coagulation in Cancer. New York, NY: Springer Publishing; 2009: 43.

  7. McMahon, B. and Friedberg, JW. Management of patients with nodular lymphocyte-predominant Hodgkin’s lymphoma.  In: Crowther, MA; Ginsberg, J; Scheunemann, HJ; Meyer, RM, and Lottenberg, R eds. Evidence-Based Hematology. Oxford, UK: Blackwell Publishing; 2008 372.